Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma (Q36747387)

From Wikidata

Jump to navigation Jump to search

scientific article published on 7 March 2013

Language	Label	Description	Also known as
English	Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma	scientific article published on 7 March 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma (English)

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

phase I clinical trial

0 references

0 references

author name string

K Yoshimura

1

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

T Minami

2

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

M Nozawa

3

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

H Uemura

4

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

language of work or name

0 references

publication date

7 March 2013

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

108

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

6

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

1260-1266

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619266

29 September 2017

Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619266

29 September 2017

A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619266

29 September 2017

Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619266

29 September 2017

Colorectal cancer vaccines: what we know and what we don't yet know

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619266

29 September 2017

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619266

29 September 2017

Natural selection of tumor variants in the generation of "tumor escape" phenotypes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619266

29 September 2017

Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619266

29 September 2017

Cleavage and polyadenylation specificity factor (CPSF)-derived peptides can induce HLA-A2-restricted and tumor-specific CTLs in the majority of gastrointestinal cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619266

29 September 2017

Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619266

29 September 2017

In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619266

29 September 2017

A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619266

29 September 2017

Role of VEGF-flt receptor system in normal and tumor angiogenesis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619266

29 September 2017

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619266

29 September 2017

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619266

29 September 2017

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619266

29 September 2017

Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619266

5 September 2018

Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619266

5 September 2018

Renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619266

5 September 2018

Induction of antigen specific cellular immunity by vaccination with peptides from MN/CA IX in renal cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619266

5 September 2018

An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619266

20 October 2018

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2013.90

21 January 2018

Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23470466

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A decade in the life of tumor immunology

1 reference

https://pubmed.ncbi.nlm.nih.gov/23470466

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation

1 reference

https://pubmed.ncbi.nlm.nih.gov/23470466

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23470466

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Detection of peptide-specific cytotoxic T-lymphocyte precursors used for specific immunotherapy of pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23470466

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23470466

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/23470466

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.2013.90

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36747387&oldid=2199268565"